HER2-targeted therapy: Monoclonal antibodies, crucial in HER2-positive breast cancer (early and metastatic), can induce cardiac dysfunction by disrupting HER-2/ERBB2-neuregulin (NRG) signaling, essential for cardiomyocyte growth, repair, and homeostasis. This evidence concerns the gene ERBB2 and breast cancer.